INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 80 filers reported holding INOZYME PHARMA INC in Q4 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6,968,750 | -41.8% | 1,562,500 | 0.0% | 1.46% | -21.2% |
Q1 2024 | $11,968,750 | +79.8% | 1,562,500 | 0.0% | 1.85% | +78.8% |
Q4 2023 | $6,656,250 | +1.4% | 1,562,500 | 0.0% | 1.04% | -48.4% |
Q3 2023 | $6,562,500 | +127.1% | 1,562,500 | +209.8% | 2.01% | +236.5% |
Q1 2023 | $2,890,252 | – | 504,407 | – | 0.60% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $27,113,000 | 10.69% |
Burrage Capital Management LLC | 242,517 | $4,132,000 | 4.14% |
CHI Advisors LLC | 927,264 | $15,801,000 | 3.68% |
Sofinnova Investments, Inc. | 2,028,308 | $34,562,000 | 1.99% |
Novo Holdings A/S | 1,867,706 | $31,826,000 | 1.41% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,178,985 | $37,130,000 | 0.66% |
RA Capital Management | 2,003,653 | $34,142,000 | 0.55% |
NEA Management Company, LLC | 2,444,379 | $41,652,000 | 0.54% |
Rock Springs Capital Management LP | 840,272 | $14,318,000 | 0.28% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 365,172 | $6,223,000 | 0.09% |